Ambroxol and pulmonary toxicity induced by antineoplastic drugs

M. Luisetti, V. Peona, M. Salmona, A. M. Pagnoni, F. Villani, R. Knerich, M. Genghini, L. Abbà, E. Pozzi

Research output: Contribution to journalArticle

Abstract

The authors describe the potential effects of ambroxol on the pulmonary disorders induced by antineoplastic agents (in particular, bleomycin and the nitrosureas). An experimental stage focussed attention on the early modifications occurring in the alveolar surfactant and in the afflux of inflammatory and immune-effector cells following bleomycin-induced lung fibrosis in the rat (by intratracheal instillation). The ambroxol-protected rats showed a slower drop of alveolar lecithins in the first few hours after bleomycin administration and a lower afflux of neutrophils, macrophages and lymphocytes. In the clinical stage, respiratory function was studied in two groups of cancer patients treated with nitrosureas or bleomycin. Preliminary findings indicate a rapid worsening of some functional parameters - maximal expiratory flow at 25% vital capacity, diffusing capacity for carbon monoxide and diffusing capacity/ventilation - in controls, while no such changes occurred in the ambroxol-protected subjects. The possible pathogenetic implications of these results and perspective for future investigations are discussed.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalInternational Journal of Clinical Pharmacology Research
Volume6
Issue number2
Publication statusPublished - 1986

Fingerprint

Ambroxol
Bleomycin
Antineoplastic Agents
Lung
Lecithins
Vital Capacity
Carbon Monoxide
Surface-Active Agents
Ventilation
Neutrophils
Fibrosis
Macrophages
Lymphocytes
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Luisetti, M., Peona, V., Salmona, M., Pagnoni, A. M., Villani, F., Knerich, R., ... Pozzi, E. (1986). Ambroxol and pulmonary toxicity induced by antineoplastic drugs. International Journal of Clinical Pharmacology Research, 6(2), 129-136.

Ambroxol and pulmonary toxicity induced by antineoplastic drugs. / Luisetti, M.; Peona, V.; Salmona, M.; Pagnoni, A. M.; Villani, F.; Knerich, R.; Genghini, M.; Abbà, L.; Pozzi, E.

In: International Journal of Clinical Pharmacology Research, Vol. 6, No. 2, 1986, p. 129-136.

Research output: Contribution to journalArticle

Luisetti, M, Peona, V, Salmona, M, Pagnoni, AM, Villani, F, Knerich, R, Genghini, M, Abbà, L & Pozzi, E 1986, 'Ambroxol and pulmonary toxicity induced by antineoplastic drugs', International Journal of Clinical Pharmacology Research, vol. 6, no. 2, pp. 129-136.
Luisetti, M. ; Peona, V. ; Salmona, M. ; Pagnoni, A. M. ; Villani, F. ; Knerich, R. ; Genghini, M. ; Abbà, L. ; Pozzi, E. / Ambroxol and pulmonary toxicity induced by antineoplastic drugs. In: International Journal of Clinical Pharmacology Research. 1986 ; Vol. 6, No. 2. pp. 129-136.
@article{0adaef2dfb2848098c05b25fb004bdaf,
title = "Ambroxol and pulmonary toxicity induced by antineoplastic drugs",
abstract = "The authors describe the potential effects of ambroxol on the pulmonary disorders induced by antineoplastic agents (in particular, bleomycin and the nitrosureas). An experimental stage focussed attention on the early modifications occurring in the alveolar surfactant and in the afflux of inflammatory and immune-effector cells following bleomycin-induced lung fibrosis in the rat (by intratracheal instillation). The ambroxol-protected rats showed a slower drop of alveolar lecithins in the first few hours after bleomycin administration and a lower afflux of neutrophils, macrophages and lymphocytes. In the clinical stage, respiratory function was studied in two groups of cancer patients treated with nitrosureas or bleomycin. Preliminary findings indicate a rapid worsening of some functional parameters - maximal expiratory flow at 25{\%} vital capacity, diffusing capacity for carbon monoxide and diffusing capacity/ventilation - in controls, while no such changes occurred in the ambroxol-protected subjects. The possible pathogenetic implications of these results and perspective for future investigations are discussed.",
author = "M. Luisetti and V. Peona and M. Salmona and Pagnoni, {A. M.} and F. Villani and R. Knerich and M. Genghini and L. Abb{\`a} and E. Pozzi",
year = "1986",
language = "English",
volume = "6",
pages = "129--136",
journal = "International Journal of Clinical Pharmacology Research",
issn = "0251-1649",
publisher = "Bioscience Ediprint Inc.",
number = "2",

}

TY - JOUR

T1 - Ambroxol and pulmonary toxicity induced by antineoplastic drugs

AU - Luisetti, M.

AU - Peona, V.

AU - Salmona, M.

AU - Pagnoni, A. M.

AU - Villani, F.

AU - Knerich, R.

AU - Genghini, M.

AU - Abbà, L.

AU - Pozzi, E.

PY - 1986

Y1 - 1986

N2 - The authors describe the potential effects of ambroxol on the pulmonary disorders induced by antineoplastic agents (in particular, bleomycin and the nitrosureas). An experimental stage focussed attention on the early modifications occurring in the alveolar surfactant and in the afflux of inflammatory and immune-effector cells following bleomycin-induced lung fibrosis in the rat (by intratracheal instillation). The ambroxol-protected rats showed a slower drop of alveolar lecithins in the first few hours after bleomycin administration and a lower afflux of neutrophils, macrophages and lymphocytes. In the clinical stage, respiratory function was studied in two groups of cancer patients treated with nitrosureas or bleomycin. Preliminary findings indicate a rapid worsening of some functional parameters - maximal expiratory flow at 25% vital capacity, diffusing capacity for carbon monoxide and diffusing capacity/ventilation - in controls, while no such changes occurred in the ambroxol-protected subjects. The possible pathogenetic implications of these results and perspective for future investigations are discussed.

AB - The authors describe the potential effects of ambroxol on the pulmonary disorders induced by antineoplastic agents (in particular, bleomycin and the nitrosureas). An experimental stage focussed attention on the early modifications occurring in the alveolar surfactant and in the afflux of inflammatory and immune-effector cells following bleomycin-induced lung fibrosis in the rat (by intratracheal instillation). The ambroxol-protected rats showed a slower drop of alveolar lecithins in the first few hours after bleomycin administration and a lower afflux of neutrophils, macrophages and lymphocytes. In the clinical stage, respiratory function was studied in two groups of cancer patients treated with nitrosureas or bleomycin. Preliminary findings indicate a rapid worsening of some functional parameters - maximal expiratory flow at 25% vital capacity, diffusing capacity for carbon monoxide and diffusing capacity/ventilation - in controls, while no such changes occurred in the ambroxol-protected subjects. The possible pathogenetic implications of these results and perspective for future investigations are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0022884823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022884823&partnerID=8YFLogxK

M3 - Article

C2 - 2424848

AN - SCOPUS:0022884823

VL - 6

SP - 129

EP - 136

JO - International Journal of Clinical Pharmacology Research

JF - International Journal of Clinical Pharmacology Research

SN - 0251-1649

IS - 2

ER -